Immunomedics Hit With CRL Over Breast Cancer Drug

Drug Industry Daily
A A
The FDA issued Immunomedics a complete response letter for a BLA seeking accelerated approval for its antibody-based breast cancer treatment, sacituzumab govitecan, for patients who have tried at least two prior treatments.

To View This Article:

Login

Subscribe To Drug Industry Daily